CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Darunavir

Last Updated: December 22, 2009
Result type: Reports
Project Number: S0194
Product Line: Reimbursement Review

Generic Name: Darunavir

Brand Name: Prezista

Manufacturer: Janssen-Ortho Inc.

Indications: HIV infection (Pediatric)

Submission Type: New Indication

Project Status: Complete

Date Recommendation Issued: June 17, 2010

Recommendation Type: List with clinical criteria and/or conditions